WO2026022749 - CBL-B INHIBITORS
National phase entry is expected:
Publication Number
WO/2026/022749
Publication Date
29.01.2026
International Application No.
PCT/IB2025/057499
International Filing Date
24.07.2025
Title **
[English]
CBL-B INHIBITORS
[French]
INHIBITEURS DE CBL-B
Applicants **
AURIGENE ONCOLOGY LIMITED
Inventors
VENKATESHAPPA, Chandregowda
BERA, Kalisankar
SAMAJDAR, Susanta
TÖRMÄKANGAS, Olli
KUMPULAINEN, Esa
TURKU, Ainoleena
Priority Data
202411056975
26.07.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3997 | |
| EPO | Filing, Examination, Granting | 40036 | |
| Japan | Filing, Examination, Granting | 3514 | |
| South Korea | Filing, Examination, Granting | 4838 | |
| USA | Filing, Examination, Granting | 33390 |
Total:
85,775
Contact Us
Abstract[English]
The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof. The compounds of formula (I) possess utility as inhibitors of Cb1-b. The compounds are useful as medicaments in the treatment of diseases or conditions wherein inhibition of Cb1-b is desired, such as cancer.[French]
La présente invention concerne un composé de formule (I) : ou un sel pharmaceutiquement acceptable de celui-ci. Les composés de formule (I) sont utiles en tant qu'inhibiteurs de Cb1-b. Les composés sont utiles en tant que médicaments dans le traitement de maladies ou d'états de santé dans lesquels l'inhibition de Cb1-b est souhaitée, par exemple le cancer.